Compare PGY & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | SPTX |
|---|---|---|
| Founded | 2016 | 2024 |
| Country | United States | United States |
| Employees | 503 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2021 | 2026 |
| Metric | PGY | SPTX |
|---|---|---|
| Price | $13.52 | $18.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | $29.45 | ★ $37.13 |
| AVG Volume (30 Days) | ★ 1.8M | 283.4K |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.43 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $1,301,360,000.00 | N/A |
| Revenue This Year | $12.99 | N/A |
| Revenue Next Year | $16.38 | N/A |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | ★ 26.07 | N/A |
| 52 Week Low | $10.40 | $15.79 |
| 52 Week High | $26.80 | $28.38 |
| Indicator | PGY | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.93 | 38.96 |
| Support Level | $12.46 | $15.79 |
| Resistance Level | $16.42 | $22.57 |
| Average True Range (ATR) | 1.01 | 1.38 |
| MACD | -0.41 | -0.33 |
| Stochastic Oscillator | 1.67 | 13.95 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.